# Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

> **NCT02765854** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 70 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02765854
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02765854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02765854, "Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02765854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*